Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
-
8801
-
8802
P63 and CD44 expression were decreased in triple mutants.
Published 2012“…Np63 was expressed in the AER and epithelial cells of E10.5 and E11.5 control (A and C) and triple mutant hindlimbs (B and D). …”
-
8803
Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure
Published 2021“…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
-
8804
Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure
Published 2021“…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
-
8805
Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure
Published 2021“…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
-
8806
-
8807
Silencing <i>ifi202</i> expression decreased T cell proliferation.
Published 2013“…<p><b>A</b>. Silencing of <i>ifi202</i> expression by <i>ifi202</i>-specific shRNA. 5KC cells were transduced with scramble shRNA-expressing lentiviral particles (5KC.scramble) and <i>ifi202</i>-specific shRNA (5KC.ifi202.shRNA), respectively. …”
-
8808
-
8809
-
8810
-
8811
-
8812
-
8813
-
8814
-
8815
Table5_Comprehensive Analysis of the Transcriptome-Wide m6A Methylation Modification Difference in Liver Fibrosis Mice by High-Throughput m6A Sequencing.DOCX
Published 2021“…Hence, the critical elements of m6A modification, including methyltransferase WTAP, demethylases ALKBH5 and binding proteins YTHDF1 were confirmed by RT-qPCR and Western blot. …”
-
8816
Expression of <i>Foxf1a</i> and <i>Foxf2</i> in <i>shh<sup>−/−</sup></i> and <i>Tbx5<sup>+/−</sup></i> mutants embryos at E9.5.
Published 2014“…<i>Tbx5</i> heterozygotes expressed <i>Foxf1a</i> at decreased levels specifically in the posterior SHF tissues (C, D), whereas <i>Foxf2</i> expression patterns were unchanged (G, H). …”
-
8817
Inhibition of MRP1 significantly decreases basal and apoptotic GSH efflux.
Published 2012“…GSH release from MRP1-silenced ARPE-19 cells incubated with 150 µM H<sub>2</sub>O<sub>2</sub> for 5 h in serum free medium. A significant decrease (P<0.001 vs scrambled control) in GSH release was observed in 5 h. …”
-
8818
Survivin deletion in beta cells leads to decreased beta-cell mass.
Published 2012“…<p>(a) Male and female mutant mice exhibit decreased beta-cell mass at 2-month of age as compared to controls (n = 5 per genotype). …”
-
8819
-
8820
GSK343 decreased viability and proliferation in human neuroblastoma PDX cells.
Published 2021“…Treatment with GSK343 resulted in significantly decreased migration. (D) After 24 hours of treatment with increasing concentrations of GSK343 (0, 5, 10 μM), COA3 and COA6 cells (4.0 × 10<sup>4</sup>) were plated in Transwell<sup>®</sup> inserts and allowed to invade for 1 week through a Matrigel<sup>™</sup> layer. …”